Decision Resources' Brand Perception Series: Physician Segmentation Uncovers Targeted Opportunities for Marketed Drug Brands and Emerging Agents With Physician Segmentation Analysis

WALTHAM, Mass., May 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, today announced the availability of the Brand Perception Series: Physician Segmentation, which identifies key physician segments to uncover targeted opportunities for current and emerging drug brands. This series offers a fresh look at a competitive drug market by analyzing physician perception of current and emerging drugs using unique physician profiles that will help biopharmaceutical companies understand and size market opportunities.

"As drug markets become saturated with brand and generic competition, it is increasingly challenging for drug marketers to formulate effective product differentiation and positioning strategies," said Decision Resources Director Nicole Westphal, Ph.D. "With Brand Perception Series: Physician Segmentation, Decision Resources identifies key segments of physicians, characterizes the segments based on demographic and behavioral variables and explores the reasons behind segments' current and emerging product perceptions to help biopharmaceutical teams build product strategies that will resonate with high-opportunity prescribers."

Four Reports Now Available

Four new reports for 2010 are now available, including:

• Brand Perceptions Series: Physician Segmentation in Chronic Obstructive Pulmonary Disease which finds that efficacy in alleviating symptoms, improving breathing and frequency of exacerbations are key drivers of brand choice across all physician segments.
• Brand Perception Series: Physician Segmentation in Major Depressive Disorder which finds that when prescribing drugs for depressed patients, safety-minded physicians in independent practices may sacrifice efficacy and/or cost for safety.
• Brand Perception Series: Physician Segmentation in Parkinson's Disease which finds that Teva/Lundbeck's Azilect is neurologists' top overall agent for the treatment of Parkinson's disease, based primarily on their favorable perception of the brand's disease modifying/neuroprotective effect.
• Brand Perception Series: Physician Segmentation in Rheumatoid Arthritis which finds that physicians perceive that different brands within the TNF-alpha inhibitor drug class have distinct strengths and weaknesses, despite clinical data suggesting that agents in this class have similar efficacy to each other.

Each report includes an analysis of physician segments based on their drivers of brand choice, along with a segment-by-segment look at both perception of currently marketed therapies and drivers of emerging therapy use.

In 2010, additional reports from Brand Perception Series: Physician Segmentation will include:

• Asthma
• Insulins
• Multiple Sclerosis
• Noninsulin Antidiabetics
• Psoriasis

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

SOURCE Decision Resources